trending Market Intelligence /marketintelligence/en/news-insights/trending/2DFUiSJGqn282-4tld484Q2 content esgSubNav
In This List

AtriCure closes acquisition of SentreHEART

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AtriCure closes acquisition of SentreHEART

AtriCure Inc. completed its acquisition of privately held SentreHEART Inc. for an up-front payment of about $40 million in a cash and stock deal.

Redwood City, Calif.-based SentreHEART develops percutaneous left atrial appendage management solutions for certain patients with an irregular heartbeat.

Mason, Ohio-based AtriCure, which develops technologies to treat atrial fibrillation, will pay an additional $140 million in milestone related payments for SentreHEART's Lariat suture delivery device and another $120 million for the therapy involving SentreHEART devices.

Piper Jaffray & Co. was the exclusive financial adviser, and Pepper Hamilton LLP served as legal counsel to ArtiCure. Guggenheim Securities LLC and Goodwin Procter LLP were SentreHEART's exclusive financial adviser and legal counsel, respectively.